Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mangoceuticals, Inc. (MGRX : NSDQ)

• Company Description    Mangoceuticals Inc. is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc. is based in DALLAS, TX. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $1.14 Daily Weekly Monthly 20 Day Moving Average: 289,836 shares Shares Outstanding: 13.91 (millions) Market Capitalization: $15.85 (millions) Beta: 2.56 52 Week High: $6.15 52 Week Low: $0.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.52% -11.44% 12 Week -55.64% -56.44% Year To Date -52.89% -59.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15110 DALLAS PKWY SUITE 600 - DALLAS,TX 75248 USA ph: 214-242-9619 fax: - investors@mangorx.com http://www.mangoceuticals.com

• General Corporate Information    Officers Jacob D. Cohen - Chief Executive Officer and Chairman Antonios Isaac - President and Director Amanda Hammer - Chief Operating Officer Eugene M. Johnston - Chief Financial Officer Lorraine D'Alessio - Director Peer Information Mangoceuticals, Inc. (GSAC) Mangoceuticals, Inc. (CASI) Mangoceuticals, Inc. (ALCD.) Mangoceuticals, Inc. (OMNN) Mangoceuticals, Inc. (CGPI.) Mangoceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 56270V205 SIC: 8090 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 13.91 Most Recent Split Date: 10.00 (0.07:1) Beta: 2.56 Market Capitalization: $15.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.01 Price/Cash Flow: - Price / Sales: 34.02 EPS Growth vs. Year Ago Period: 30.30% vs. Previous Quarter: -21.05% Sales Growth vs. Year Ago Period: -36.84% vs. Previous Quarter: -50.00% ROE 09/30/25 - -114.63 06/30/25 - -85.01 03/31/25 - -72.81 ROA 09/30/25 - -106.42 06/30/25 - -78.08 03/31/25 - -66.58 Current Ratio 09/30/25 - 0.74 06/30/25 - 0.07 03/31/25 - 0.12 Quick Ratio 09/30/25 - 0.74 06/30/25 - 0.07 03/31/25 - 0.12 Operating Margin 09/30/25 - -4,253.43 06/30/25 - -2,757.86 03/31/25 - -2,191.76 Net Margin 09/30/25 - -4,253.43 06/30/25 - -2,757.86 03/31/25 - -2,191.76 Pre-Tax Margin 09/30/25 - -4,253.65 06/30/25 - -2,757.86 03/31/25 - -2,191.76 Book Value 09/30/25 - 1.13 06/30/25 - 1.81 03/31/25 - 3.92 Inventory Turnover 09/30/25 - - 06/30/25 - 60.95 03/31/25 - 31.81 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©